top of page
Pipetting Samples
World's First
Severe Dengue
Prediction Assay
Empowering Personalized Medicine for Tomorrow

At StratifiCare, we specialize in the development and manufacturing of in-vitro diagnostic assay solutions for personalized medicine.


This offers the right treatment for the right patient at the right time while eliminating the inefficient trial-and-errors for optimal patient care and reduced treatment cost.



The Challenge


Currently, doctors are unable to predict the progress of the disease due to the lack of a Severe Dengue prediction test. Patients often end up being admitted to hospital even when they do not progress to Severe Dengue. This leads to overhospitalization in both developing and developed countries.

Our Solution


StratifiDen is a patented, breakthrough test that measures specific biomarkers to predict the risk of severe dengue. It streamlines the standard of care, ensuring each patient receives the appropriate treatment and reduce over-hospitalisation issued faced by hospitals.

The Challenge


Y90 radioembolization (RE), also known as transarterial radioembolization (TARE), is one of the treatment options for unresectable hepatocellular carcinoma (HCC). Currently, only 2-3 out of 10 HCC patients respond to Y90 RE treatment. The 3 to 6-month post-treatment wait can be agonising

Our Solution


StratifiREY uses a panel of white blood cell biomarkers to determine if the patient is able to respond to Y90 RE. This provides patients with early insights into Y90 RE treatment effectiveness, guiding them toward the best treatment path without an agonizing wait.



For Enquiry or Collaboration

Keen on making a difference? We'd love to hear from you!

bottom of page